DK1235072T3 - Surrogater for målmolekyler og forbedrede referencefelter - Google Patents

Surrogater for målmolekyler og forbedrede referencefelter

Info

Publication number
DK1235072T3
DK1235072T3 DK02009879T DK02009879T DK1235072T3 DK 1235072 T3 DK1235072 T3 DK 1235072T3 DK 02009879 T DK02009879 T DK 02009879T DK 02009879 T DK02009879 T DK 02009879T DK 1235072 T3 DK1235072 T3 DK 1235072T3
Authority
DK
Denmark
Prior art keywords
reactivity
receptor
panel
panels
members
Prior art date
Application number
DK02009879T
Other languages
Danish (da)
English (en)
Inventor
Lawrence M Kauvar
Hugo O Villar
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/177,673 external-priority patent/US5587293A/en
Application filed by Telik Inc filed Critical Telik Inc
Application granted granted Critical
Publication of DK1235072T3 publication Critical patent/DK1235072T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Laminated Bodies (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Forklifts And Lifting Vehicles (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Control Of Driving Devices And Active Controlling Of Vehicle (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DK02009879T 1994-01-06 1995-01-05 Surrogater for målmolekyler og forbedrede referencefelter DK1235072T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/177,673 US5587293A (en) 1994-01-06 1994-01-06 Method to identify binding partners
US08/308,813 US5798275A (en) 1994-01-06 1994-09-19 Profiling reference panel enriched by non-IG proteins
PCT/US1995/000081 WO1995018969A1 (en) 1994-01-06 1995-01-05 Surrogates for targets and improved reference panels

Publications (1)

Publication Number Publication Date
DK1235072T3 true DK1235072T3 (da) 2007-07-16

Family

ID=26873529

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02009879T DK1235072T3 (da) 1994-01-06 1995-01-05 Surrogater for målmolekyler og forbedrede referencefelter
DK95906754T DK0738390T3 (da) 1994-01-06 1995-01-05 Surrogater for targetmolekyler og forbedrede referencepaneler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK95906754T DK0738390T3 (da) 1994-01-06 1995-01-05 Surrogater for targetmolekyler og forbedrede referencepaneler

Country Status (11)

Country Link
US (1) US5741653A (de)
EP (1) EP0738390B1 (de)
JP (1) JPH09507300A (de)
AT (2) ATE236401T1 (de)
AU (1) AU700497B2 (de)
CA (1) CA2178096C (de)
DE (2) DE69530179T2 (de)
DK (2) DK1235072T3 (de)
ES (2) ES2284743T3 (de)
PT (1) PT738390E (de)
WO (1) WO1995018969A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4767371B2 (ja) 1996-01-17 2011-09-07 インペリアル・イノベイションズ・リミテッド 細胞障害性ｔリンパ球（ｃｔｌ）を用いた免疫療法
US6054286A (en) * 1996-06-18 2000-04-25 Telik, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
AU5902098A (en) * 1997-01-03 1998-07-31 Terrapin Technologies, Inc. Method to classify gene products
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
HU225767B1 (en) 1997-11-12 2007-08-28 Dimensional Pharmaceuticals 3 High throughput method for functionally classifying proteins identified using a genomics approach
JP2002508507A (ja) * 1997-12-18 2002-03-19 セプラコア インコーポレーテッド 新規な生物学的標的および創薬リード構造体の同時同定方法
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
CA2339581A1 (en) * 1998-08-05 2000-02-17 University Of Pittsburgh Modelling organic compound reactivity in cytochrome p450 mediated reactions
US6625547B1 (en) 1998-08-05 2003-09-23 Washington State University Research Foundation Relative rates of cytochrome p450 metabolism
DE69933679T2 (de) * 1998-08-12 2007-08-23 Zycos Inc., Cambridge Darstellung des profils und katalogisierung von exprimierten proteinmarkern
US20040224338A1 (en) * 1998-08-12 2004-11-11 Zycos Inc., A Delaware Corporation Profiling and cataloging expressed protein tags
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6569631B1 (en) 1998-11-12 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay for ligand development using 5-(4″dimethylaminophenyl)-2-(4′-phenyl)oxazole derivative fluorescent dyes
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6875575B1 (en) 1998-11-25 2005-04-05 Osi Pharmaceuticals, Inc. Diagnostic methods for neoplasia
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
EP3712897A1 (de) * 2019-03-22 2020-09-23 Tata Consultancy Services Limited Automatisierte vorhersage der biologischen reaktion von chemischen verbindungen auf der basis chemischer informationen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT55143A (en) * 1987-10-13 1991-04-29 Terrapin Diagnostics Inc Method for obtaining immunodiagnostic reagents
US4963263A (en) * 1988-03-24 1990-10-16 Terrapin Technologies, Inc. Method of identity analyte-binding peptides
US5217869A (en) * 1987-10-13 1993-06-08 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5300425A (en) * 1987-10-13 1994-04-05 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5133866A (en) * 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
US5338659A (en) * 1991-04-02 1994-08-16 Terrapin Technologies, Inc. Method for determining analyte concentration by cross-reactivity profiling
US5340474A (en) * 1988-03-24 1994-08-23 Terrapin Technologies, Inc. Panels of analyte-binding ligands
IE904705A1 (en) * 1989-12-29 1991-07-17 Univ Technologies Int Methods for modelling tertiary structures of biologically¹active ligands including agonists and antagonists thereto¹and novel synthetic antagonists based on angiotensin
EP0556327A1 (de) * 1990-11-09 1993-08-25 Verigen, Inc. Methode zur bestimmung der sensitivität und/oder spezifität eines testsystems um antikörper zu detektieren

Also Published As

Publication number Publication date
AU1522195A (en) 1995-08-01
CA2178096A1 (en) 1995-07-13
WO1995018969A1 (en) 1995-07-13
PT738390E (pt) 2003-07-31
DE69535463T2 (de) 2008-01-03
AU700497B2 (en) 1999-01-07
ES2196056T3 (es) 2003-12-16
EP0738390A1 (de) 1996-10-23
EP0738390B1 (de) 2003-04-02
ES2284743T3 (es) 2007-11-16
DE69535463D1 (de) 2007-05-24
DE69530179T2 (de) 2004-04-08
US5741653A (en) 1998-04-21
JPH09507300A (ja) 1997-07-22
DK0738390T3 (da) 2003-07-21
ATE236401T1 (de) 2003-04-15
CA2178096C (en) 2004-03-09
DE69530179D1 (de) 2003-05-08
ATE359509T1 (de) 2007-05-15

Similar Documents

Publication Publication Date Title
DK1235072T3 (da) Surrogater for målmolekyler og forbedrede referencefelter
DK0933082T3 (da) Fremgangsmåde til manipulation af celledifferentiering
BR9809443A (pt) Polipeptìdeo compreendendo uma porção antigênica de um antìgeno de m. tuberculosis, molécula de dna, vetor recombinante de expressão, célula hospedeira, processo para detecção de infecção de m. tuberculosis em uma amostra biológica, kit de diganóstico, anticorpo monoclonal, anticorpo policlonal, e, proteìna de fusão.
BR9508417A (pt) Acido nucléico isolado cdna isolado proteina isolada vetor de expressão processo para detectar câncer e pré-câncer de pulmão processo para selecionar especimes humanas para proteina hcaviii processo para testar amostra de célula humana anticorpo e composição terapêutica
DK0749325T3 (da) Bispecifikke molekyler med klinisk anvendelse
DE69321218D1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
KR960702906A (ko) 면역화학적 간이 반정량방법 및 장치(simple immunochemical semiquantitative assay method and apparatus)
ATE113962T1 (de) Von polypeptiden induzierte monoklonale antikörper gegen oncoproteine.
BR9106217A (pt) Processo para a analise de uma amostra de gas,disposicao de analise,empregos disto e instalacao de teste com a citada disposicao
DE59814441D1 (de) Verwendung von kontrollflächen zur detektion von störproben in einem nachweisverfahren
DK159826C (da) Monoklonalt antistof af typen igg1, og fremgangsmaade til fremstilling deraf, fremgangsmaade til bestemmelse af hba1c samt diagnostisk kit til brug derved
Segura et al. Procedures for monitoring recombinant erythropoietin and analogues in doping control
DK1117685T3 (da) Behandling af inflammatorisk sygdom
DE69018968D1 (de) BLUTGERINNUNGSFAKTOR BETA XIIa MONOKLONALE ANTIKÖRPER UND IMMUNANALYSE.
DK26587A (da) Monoklonalt antistof, maalemetode for glucosyleret protein ved anvendelse af det monoklonale antistofog kit omfattende dette
ATE186553T1 (de) Competitives enzym-testverfahren zum nachweis von phosphothioaten
SE0003566D0 (sv) A method for the quantitative determination of one or more compounds
ATE118018T1 (de) Menschliches macrophageentzündungsprotein-2-beta.
Gooderham In situ peptide mapping of proteins following polyacrylamide gel electrophoresis
Xiang et al. Elution-modified displacement chromatography coupled with electrospray ionization-MS: on-line detection of trace peptides at low-femtomole level in peptide digests
DE69316388D1 (de) CRF Bindungsproteine
Geoghegan Modification of amino groups
DK162726C (da) Fremgangsmaade til eliminering af falsk positive resultater ved bestemmelse af atl virus-antistof og reagens dertil
Dunn Quantitative amino acid analysis
Murthy Identification of false-positive CK-MB activity in an elderly patient